Similar articles for PMID: 36635088

Year	Number of Results
1999	1
2010	1
2011	3
2012	1
2014	5
2015	2
2016	5
2017	10
2018	14
2019	15
2020	25
2021	15
2022	12
2023	1

1

Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy.

Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Gudenkauf LM, et al. J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946. Online ahead of print. J Nucl Med. 2023. PMID: 36635088

2

Advances in ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.

Ling SW, de Blois E, Hooijman E, van der Veldt A, Brabander T. Ling SW, et al. Pharmaceutics. 2022 Oct 11;14(10):2166. doi: 10.3390/pharmaceutics14102166. Pharmaceutics. 2022. PMID: 36297601 Free PMC article. Review.

3

Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.

Sandhu S, Guo C, Hofman MS. Sandhu S, et al. J Nucl Med. 2021 Aug 12;62(12):1660-8. doi: 10.2967/jnumed.120.243295. Online ahead of print. J Nucl Med. 2021. PMID: 34385339 Free PMC article.

4

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.

Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR. Miyahira AK, et al. Prostate. 2020 Nov;80(15):1273-1296. doi: 10.1002/pros.24056. Epub 2020 Aug 31. Prostate. 2020. PMID: 32865839 Free PMC article. Review.

5

Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received ¹⁷⁷Lu PSMA I&T therapy.

Bülbül O, Ünek İT, Kefi A, Tuna EB, Bekiş R. Bülbül O, et al. Hell J Nucl Med. 2020 Sep-Dec;23(3):229-239. doi: 10.1967/s002449912201. Epub 2020 Dec 14. Hell J Nucl Med. 2020. PMID: 33306752 Free article.

6

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.

Iravani A, Violet J, Azad A, Hofman MS. Iravani A, et al. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):38-52. doi: 10.1038/s41391-019-0174-x. Epub 2019 Oct 8. Prostate Cancer Prostatic Dis. 2020. PMID: 31595044 Review.

7

Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C.

Jafari E, Ahmadzadehfar H, Bagheri D, Amini A, Assadi M. Jafari E, et al. Nucl Med Commun. 2021 Mar 1;42(3):325-331. doi: 10.1097/MNM.0000000000001327. Nucl Med Commun. 2021. PMID: 33306634

8

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.

9

Radiation protection in therapy with radiopharmaceuticals.

Hosono M. Hosono M. Int J Radiat Biol. 2019 Oct;95(10):1427-1430. doi: 10.1080/09553002.2018.1516910. Epub 2018 Sep 28. Int J Radiat Biol. 2019. PMID: 30265162

10

Relevance of radiobiological concepts in radionuclide therapy of cancer.

Kumar C, Shetake N, Desai S, Kumar A, Samuel G, Pandey BN. Kumar C, et al. Int J Radiat Biol. 2016;92(4):173-86. doi: 10.3109/09553002.2016.1144944. Epub 2016 Feb 26. Int J Radiat Biol. 2016. PMID: 26917443 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed